gallbladder and glp 1 GLP-1 receptor agonists disease risk: insights into molecular mechanisms and clinical implications Liraglutide Linked to Gallbladder Complications

Originally approved by the FDA for the treatment of adult obesity in 2014, the drug received authorisation in 2020 for obesity in adolescents aged 12-17 years old (Mller, Blher, Tschp, DiMarchi)

Erratum in: Diabetes Care

People with a history of pancreatitis or those with risk factors for the condition may need to avoid these medications

Please update your browser for more security and a better experience

Bossowski A, Moniuszko M, Dbrowska M, et al

They do this by binding to receptors in the pancreas, brain, and gastrointestinal tract, disrupting natural hunger signaling by increasing insulin release, inhibiting glucagon, and delaying stomach emptying